Oct 6, 2025 · Harrow is redefining the standard of care in eyecare with a portfolio of trusted, high-value pharmaceutical solutions that deliver proven safety, efficacy, and affordability.

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …

At Harrow, we’re passionate about making eyecare more innovative, accessible, and affordable for everyone. Whether you're an eyecare professional, a patient, or a current — or future — member of …

Harrow, a leading provider of ophthalmic disease management solutions in North America, was founded with a commitment to deliver safe, effective, accessible, and affordable medications that enhance …

Nov 18, 2025 · Integration into Harrow: Melt Pharmaceuticals will be fully integrated into Harrow’s operations to ensure a seamless transition and accelerate progress toward NDA submission, …

In September 2025, Harrow announced the launch of Harrow Access for All (HAFA), expanding Harrow’s commitment to make it easier and more affordable for patients to access Harrow’s full …

The Investor Relations website contains information about Harrow, Inc.'s business for stockholders, potential investors, and financial analysts.

Sep 26, 2025 · By re-joining Harrow, we gain the resources and expertise needed to accelerate our programs and bring MELT-300 closer to the patients and physicians who need it most.

Aug 12, 2025 · Harrow, Inc. Investor & Analyst Day Presentation 6.8 MB August 13, 2025 | 1:00 PM EDT H.C. Wainwright’s 5th Annual Ophthalmology Conference - Panel discussion on Novel …

Prior to joining Harrow, he was Founder and Chief Executive Officer of LVMA Consulting, advising emerging biotech companies and top 10 global pharmaceutical organizations on commercial …